Crossmark

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials

Crossref DOI link: https://doi.org/10.1007/s11255-026-05064-w

Published Online: 2026-02-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zou, Qi

Huang, Qiao

Li, Jiashuo

Li, Qiang
License Information

Text and Data Mining valid from 2026-02-26

Version of Record valid from 2026-02-26
More Information

Article History

Received: 20 January 2026

Accepted: 16 February 2026

First Online: 26 February 2026

Declarations

:

: The authors declare no competing interests.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Not applicable.

Document is current

Any future updates will be listed below